• Chemotherapy
• Immunotherapy
• Targeted Drug Therapy

• Sr Consultant Apollo hospital Jan 2000 - Present23 years 7 months
• Associate consultant Dr. S.H. Advani Nov 2002 - Jul 20052 years 9 months

• MBBS - Sambalpur University, 1991
• MD - General Medicine - Berhampur University, 1995
• DM - Medical Oncology - All India Institute of Medical Sciences, New Delhi, 2000

• Nominated for Medical Excellence Award for excellence in the field of Oncology in India by Harvard Medical International Community Service. (From Harvard Medical School)
• Organizing cancer awareness camps at various schools, colleges, universities, and corporate houses at regular intervals for the past ten years.
• Conducting seminars in different parts of India & teaching general practitioners about the importance of cancer screening, early diagnosis, and prevention.

• Selected as an Expert committee member of Drug Controller General of India
• Member American Society of Clinical Oncology. (Since 2000)
• Life member European Society of Medical Oncology.(Since 2012)
• Lifetime member of ISMPO (Indian Society of Medical and Pediatric Oncology))

RESEARCH WORK

• Role of circulating micromegakaryocytes in Chronic Myeloid Leukemia
• Response of CHOP chemotherapy in Intermediate and high grade Non Hodgkin’s Lymphoma
• To evaluate the efficacy of Sorafenib tosylate and Paclitaxel by measuring tumor response, as defined by RECIST criteria, in patients with metastatic, Her-2 Negative Breast Cancer.( P.I)
• Role of IV FOSPREPITANT in prevention of chemotherapy induced nausea & vomiting (PI )
• A Randomized two –arm , open – label multicenter Phase 2 trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients with HER2- positive and hormone receptor – positive advanced ( metastatic or locally advanced) breast cancer (PI)
• Epidemiological study to evaluate the prevalence of epidermal growth factor receptor ( EGGR) mutation status in Non- Small Cell Lung Cancer ( P.I.)
• A Phase III Multicenter, Randomized Study of Oral LDK378 Vs. Standard Chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), Stage IIIB or IV, Non-Squamous Non-Small Cell Lung Cancer (P.I.)
• A Phase 3, Double blind, randomized, parallel group active controlled study to compare the efficacy and safety of CT-P6 versus Herceptin as Neoadjuvant and Adjuvant treatment in patients with Her2-positive Early Breast Cancer (Co. Investigator)
• A Phase III, randomized, double blind, active controlled, parallel group study, conducted under in-house blinding conditions, to examine the safety, tolerability and efficacy of a single dose of intravenous MK-0517 for prevention of chemotherapy-induced nausea and vomiting. (P.I.)
• A double blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with Paclitaxel in patients with Locally Recurrent or Metastatic Breast Cancer. (P.I.)
• A randomized, double blind, placebo controlled, multicenter Phase II Anamorelin HCl Dose Range study to evaluate the safety and efficacy of Anamorelin Hcl in Patients with NSCLC. (P.I.)
• Post marketing (phase IV) trial to monitor the adverse events of Fosaprepitant (EMEND ® IV) in prevention of chemotherapy induced nausea vomiting (CINV) in patients receiving moderate or high emetogenic chemotherapy in usual practice in India. (P.I.))
• An open label, multicenter, expanded treatment protocol (ETP) of oral LDK378 in adult patients with non-small cell lung cancer (NSCLC) characterized by ALK positivity. (P.I.)
• Prospective single arm Post-Marketing Phase IV study to assess the safety and efficacy of Lenvatinib in subjects with Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid cancer. ( P.I)
• A phase II/III, pivotal, open label, randomized 3 arm study to assess safety and efficacy of LNP3794 monotherapy or in combination with Docetaxel, compared with Docetaxel alone, in patients with RAS mutation positive locally advanced and metastatic Non-Small Cell Lung Cancer. (P.I.)
• A Phase study to investigate the safety & efficacy of Regorafenib in Indian Patients with Metastatic Colorectal Cancer (mCRC). ( P.I.)
• A Prospective, Open- label, Phase 4 Study to Evaluate the Safety of Pembrolizumab ( KEYTRUDA (R) in Subjects with Unrespectable or Metastatic Melanoma or PDL-1 positive Non- Small Cell Lung Cancer (NSCLC) in India ( Keynote -593)“ (P.I.)
• A Prospective, Single – arm , Multicenter, Pragmatic Phase- IV Trial Investigating safety and Effectiveness of DARZALEX ( Daratumumab) In Indian Subjects with Relapsed and Refractory Multiple Myeloma , whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Protocol No: 54767414MMY4008 (P.I.)
• A Prospective, Multicenter, Open –Label Single arm Phase- IV Clinical Trial to Assess the Safety of Lmbruvica Tm( Ibrutinib Capsules 140 mg ) in Indian patients with Chronic Lymphocytic Leukemia of Mantle Cell Lymphoma who have received at least one prior therapy or chronic Lymphocytic leukemia with 17p Deletion Protocol No : 54179060LYM4005 (P.I.)